SCHEMBL394230

SCHEMBL394230

Cc1[nH]c(C=C2C(=O)Nc3cc(NC(=O)c4ccccc4)ccc32)c(C)c1C(=O)NCCN(C)C

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 4/20 0.65
AURKB Q96GD4 2/20 0.65
PRKAA1 Q13131 8/20 0.65
KDR P35968 8/20 0.65
PRKAA2 P54646 7/20 0.65
PDGFRB P09619 3/20 0.65
FGFR1 P11362 3/20 0.65
CSF1R P07333 4/20 0.61
FLT4 P35916 2/20 0.61
KIT P10721 2/20 0.61
NTRK2 Q16620 1/20 0.59
EGFR P00533 1/20 0.57
NEK2 P51955 1/20 0.57
MELK Q14680 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091945 1.00 FLT3 (0.65) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL396405 0.95 NTRK2 (0.65) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL10091892 0.95 NTRK2 (0.65) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL10091886 0.93 FLT3 (0.61) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL394109 0.93 FLT3 (0.61) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL10091843 0.92 KDR (0.75) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL399057 0.92 KDR (0.75) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL10091852 0.90 NTRK2 (0.67) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL393779 0.90 NTRK2 (0.67) FLT3AURKBPRKAA1KDRPRKAA2
SCHEMBL10091894 0.88 KDR (0.69) FLT3AURKBPRKAA1KDRPRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US disclosed